Monalizumab

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced the filing of its 2025 Universal Registration Document ( Document d’enregistrement universel ) for the year ending December 31, 2025 with the French market authority “Autorité des Marchés Financiers” (“ AMF ”) on April 1 st , 2026. It can be downloaded (in French) on the Company’s website and on the AMF’s website . The following documents are incorporated into the Universal Registration Document: the annual financial report, the annual management report, the corporate governance report provided for under Article L. 225-37 of the French Commercial Code, the report of Statutory Auditors. The Company also announced today the filing of its Form 20-F annual report for the year ending December 31, 2025 with the United States Securities and Exchange Commission (“ SEC ”) on April 1 st , 2026. It can be also be accessed on the Company’s website and on the SEC’s website . About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics. Innate Pharma is advancing a portfolio of differentiated potential first and/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer. Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at and follow us on LinkedIn and X . Information about Innate Pharma shares ISIN code Ticker code LEI FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 Disclaimer on forward-looking information and risk factors For a discussion of risks and uncertainties, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website or on Innate Pharma’s website ( ), and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. Contacts investors & Media Relations Innate Pharma Stéphanie Cornen stephanie.cornen@innate-pharma.fr Investor Relations investors@innate-pharma.fr Media communication@innate-pharma.fr

Back in September, IPH6501 wasn’t named among the most valued candidates in Innate’s pipeline.\n Innate Pharma has finally called time on an NK cell engager in phase 1/2 development as part of an ongoing fine-tuning of the French biotech’s pipeline.The Marseille-headquartered company had been evaluating IPH6501, a tetraspecific antibody-based natural killer cell engager, in a phase 1/2 study for B-cell non-Hodgkin lymphoma. As recently as November, Innate had been planning to enroll up to 184 patients across the U.S., Australia and France.But the biotech disclosed in its full-year 2025 earnings results Thursday that the study has been “discontinued as part of the company’s strategic prioritization of its pipeline.” Innate had previously reported that the dose-escalation portion of the trial had already been completed, and the biotech explained this morning that data from the study would be presented at some point this year.The decision to end the trial is part of a larger strategic rethink at the company, which saw Innate lay off 30% of its employees last year to focus on its “highest-value assets.” At the time of that move, IPH6501 wasn’t named among the most valued candidates in Innate’s pipeline, suggesting that the drug’s days could be numbered.Instead, the company said at the time that it wanted to focus on assets such as IPH4502, a Nectin-4-targeting antibody-drug conjugate (ADC) undergoing a phase 1 study for a range of solid tumors. In this morning’s release, Innate CEO Jonathan Dickinson said the company believes IPH4502 has “best-in-class potential among Topo I-based Nectin-4 ADCs.” Dickinson pointed to “early signs of anti-tumor activity in heavily pre-treated patients,” including in patients with urothelial cancer who have already received Astellas’ ADC Padcev. Another drug in the spotlight is lacutamab, an anti-KIR3DL2 antibody that Innate is gearing up for a phase 3 study in an aggressive skin cancer called Sézary syndrome. There’s also the AstraZeneca-partnered anti-NKG2A antibody monalizumab, which is being evaluated in a phase 3 study for non-small cell lung cancer. Dickinson described that readout as a “key catalyst for Innate.” Innate first penned a collaboration with Sanofi back in 2016 to work on various drugs from Innate’s NK cell engager platform, dubbed ANKET. But in April 2025, Sanofi decided to hand back a CD123-targeting drug, known as SAR443579 or IPH6101, to Innate.In this morning’s release, Innate confirmed that Sanofi had deprioritized another asset from that agreement, namely a trifunctional BCMA-targeting NK cell engager called IPH6401 or SAR’514. Sanofi retains the rights to develop or commercialize the drug in the future, Innate noted.